Clinical trials on B cell prolymphocytic leukemia (B-PLL)

  • CT-EU-00111551

    Long-term follow-up of patients with various types of leukemia, including CLL, SLL, HCL and others

    This is a comprehensive study focusing on the long-term follow-up of patients diagnosed with a variety of blood and lymph node cancers, including chronic lymphocytic leukemia (CLL), B lymphocytic leukemia (B-PLL), T lymphocytic leukemia (T-PLL), small lymphocytic lymphoma (SLL), large granular T/Natural Killer (T or NK-LGL) leukemia, Hairy Cell Leukemia (HCL) and Richter’s transformation. This study aims to gather detailed information on the progression of these diseases, the effectiveness of treatment over time, and any long-term side effects or complications that may occur as a result of treatment.

    One of the key aims of this registry is to understand how therapies, particularly those involving the drug rituximab in combination with chemotherapy, affect patients’ overall survival. The study is particularly interested in long-term outcomes and any late toxicities that may occur as a result of treatment, such as secondary tumors or infections. This is important because, although some therapies can prolong life, they can also lead to other health problems in the future.

    The registry is unique because it focuses not only on CLL, but also on other rare lymphoproliferative malignancies that are closely related to CLL. There is a significant need for more information on these diseases, as they are considered orphan diseases and long-term follow-up data is scarce.

    For patients participating in this study, the main parameter measured is overall survival, meaning that the study will track how long patients live from inclusion in the registry until death. This information will be collected for up to 12 years, providing valuable insight into the long-term effects of treatment and progression of these diseases. This study is crucial for gaining a more profound understanding of CLL and related diseases, how to treat them effectively, and how to manage any long-term consequences of treatment. It represents an important step forward in improving care and outcomes for patients with these conditions.